| DC10372 |
Amcasertib(BBI503)
Featured
|
Amcasertib(BBI503) is an orally administered investigational agent designed to inhibit cancer stem cell pathways, including Nanog, by targeting stemness kinases. |
|
| DC11163 |
AST-3424
Featured
|
AST-3424 (OBI-3424, TH-3424) is a first-in-class, novel prodrug that selectively targets cancers overexpressing the enzyme AKR1C3, OBI-3424 is a highly selective prodrug that is converted by AKR1C3 to a DNA alkylating agent. |
|
| DC5032 |
AZD1480
Featured
|
AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1/2. |
|
| DC11295 |
AZD-4573 |
AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14. |
|
| DC10092 |
BLU554(Fisogatinib)
Featured
|
BLU-554 is a potent fibroblast growth factor receptor 4 (FGFR4) inhibitor. |
|
| DC2019 |
Brivanib (bms-540215)
Featured
|
Brivanib is an ATP-competitive inhibitor against human VEGFR2 and FGFR with IC50 of 25 nM and 148 nM, respectively. |
|
| DC10440 |
Namodenoson (CF-102)
Featured
|
CF-102(2-Cl-IB-MECA) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively.
target: A3 adenosine receptor agonist; |
|
| DC10559 |
Derazantinib (ARQ 087)
Featured
|
Derazantinib (Derazantinib) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively. |
|
| DC5065 |
Golvatinib (E7050)
Featured
|
E-7050 is hepatocyte growth factor receptors (HGFR). |
|
| DCAPI1441 |
Seocalcitol |
EB1089 is an analog of 1,25 dihydroxyvitamin D which acts as a vitamin D receptor (VDR). EB1089 is noted to reverse hypercalcemia and is a potent inhibitor of PTH-rP (parathyroid hormone-related peptide, PTHRP) in vitro. In studies utilizing a squamous ca |
|
| DC10128 |
FGF401( Roblitinib)
Featured
|
FGF401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. |
|
| DC11086 |
Foslinanib |
Foslinanib (TRX-818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation. |
|
| DC10033 |
H3B-6527
Featured
|
H3B-6527 is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. |
|
| DC4105 |
Linsitinib(OSI-906)
Featured
|
OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R and IR with IC50 of 35 nM and 75 nM, respectively. |
|
| DC7808 |
Refametinib (BAY86-9766)
Featured
|
Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively. |
|
| DC7261 |
Resminostat hydrochloride (4SC-201) |
Resminostat(RAS2410; 4SC-201) is a potent inhibitor of HDAC1/3/6(IC50=43-72 nM); less potent to HDAC8 with IC50 of 877 nM. |
|
| DC11812 |
SF-1126 |
SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins. |
|
| DC7065 |
Tivantinib (ARQ 197)
Featured
|
Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. |
|
| DC11087 |
TRX-818 sodium |
TRX-818 sodium (Foslinanib sodium ) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation. |
|
